Abstract
Viral sequencing has been critical in the COVID-19 pandemic response, but sequencing and bioinformatics capacity remain inconsistent. To examine the utility of a cloud-based sequencing analysis platform for SARS-CoV-2 sequencing, we conducted a cross-sectional study incorporating seven countries in July 2022. Sites submitted sequential SARS-CoV-2 sequences over two weeks to the Global Pathogen Analysis Service (GPAS). The GPAS bioinformatics cloud platform performs sequence assembly plus lineage and related sample identification. Users can share information with collaborators while retaining data ownership. Seven sites contributed sequencing reads from 5,346 clinical samples, of which 4,799/5,346 (89.8%) had a lineage identified. Omicron lineages dominated, with the vast majority being BA.5, BA.4 and BA.2, commensurate with contemporary genomic epidemiological observations. Phylogenetic analysis demonstrated low within-lineage diversity, and highly similar sequences present in globally disparate sites. A cloud-based analysis platform like GPAS addresses bioinformatics bottlenecks and facilitates collaboration in pathogen surveillance, enhancing epidemic and pandemic preparedness.
Competing Interest Statement
AvG and NW have received grant funding from Sanofi and The Bill and Melinda Gates Foundation.
Funding Statement
GPAS is free at the point of use for users in Low and Middle-Income Countries. GPAS was developed specifically to minimise the need for bioinformatics staff (a scarce and expensive resource), to help bring genomic insights within reach for laboratories with limited resources. GPAS operates as a non-profit organisation. All GPAS SARS-CoV-2 services were offered free of charge to all sites for the purposes of this study. Staff costs for the 5C analysis team were met by the University of Oxford. The cloud infrastructure used in this study was donated by Oracle Corporation. Sequencing activities for NICD are supported by a conditional grant from the South African National Department of Health as part of the emergency COVID-19 response; a cooperative agreement between the National Institute for Communicable Diseases of the National Health Laboratory Service and the United States Centers for Disease Control and Prevention (NU51IP000930); the South African Medical Research Council (SAMRC) with funds received from the South African Department of Science and Innovation; the African Society of Laboratory Medicine (ASLM) and Africa Centers for Disease Control and Prevention through a sub-award from the Bill and Melinda Gates Foundation grant number INV-018978; Africa PGI, the UK Foreign, Commonwealth and Development Office and Wellcome (Grant no 221003/Z/20/Z); and the Department of Health and Social Cares Fleming Fund using UK aid. NICD sequencing was also supported by The Coronavirus Aid, Relief, and Economic Security Act (CARES ACT) through the Centers for Disease Control and Prevention (CDC) and the COVID International Task Force (ITF) funds through the CDC under the terms of a subcontract with the African Field Epidemiology Network (AFENET) AF-NICD-001/2021. Genomic surveillance conducted in Vietnam was supported by the Wellcome Trust (222574/Z/21/Z). L.V.T. is supported by the Wellcome Trust of Great Britain (204904/Z/16/Z and 226120/Z/22/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Services Ethics lead of University of Oxford waived the requirement for ethical review for this work. We can provide a letter from University of Oxford research sponsorship and ethics lead, confirming that this study did not require review according to UK Health Research Authority requirements.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Submitted sequencing reads (free from human reads) for all included samples are available online from European Nucleotide Archive study accession PRJEB70597
